Literature DB >> 15510161

High interstitial fluid pressure - an obstacle in cancer therapy.

Carl-Henrik Heldin1, Kristofer Rubin, Kristian Pietras, Arne Ostman.   

Abstract

Many solid tumours show an increased interstitial fluid pressure (IFP), which forms a barrier to transcapillary transport. This barrier is an obstacle in tumour treatment, as it results in inefficient uptake of therapeutic agents. There are a number of factors that contribute to increased IFP in the tumour, such as vessel abnormalities, fibrosis and contraction of the interstitial matrix. Lowering the tumour IFP with specific signal-transduction antagonists might be a useful approach to improving anticancer drug efficacy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15510161     DOI: 10.1038/nrc1456

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  606 in total

1.  Coadministration of a tumor-penetrating peptide improves the therapeutic efficacy of paclitaxel in a novel air-grown lung cancer 3D spheroid model.

Authors:  Sweta K Gupta; Elisa A Torrico Guzmán; Samantha A Meenach
Journal:  Int J Cancer       Date:  2017-08-18       Impact factor: 7.396

2.  Interstitial fluid pressure correlates with intravoxel incoherent motion imaging metrics in a mouse mammary carcinoma model.

Authors:  Sungheon Kim; Lindsey Decarlo; Gene Y Cho; Jens H Jensen; Daniel K Sodickson; Linda Moy; Silvia Formenti; Robert J Schneider; Judith D Goldberg; Eric E Sigmund
Journal:  NMR Biomed       Date:  2011-11-09       Impact factor: 4.044

3.  Mild elevation of body temperature reduces tumor interstitial fluid pressure and hypoxia and enhances efficacy of radiotherapy in murine tumor models.

Authors:  Arindam Sen; Maegan L Capitano; Joseph A Spernyak; John T Schueckler; Seneca Thomas; Anurag K Singh; Sharon S Evans; Bonnie L Hylander; Elizabeth A Repasky
Journal:  Cancer Res       Date:  2011-04-21       Impact factor: 12.701

4.  Vessel-Targeted Chemophototherapy with Cationic Porphyrin-Phospholipid Liposomes.

Authors:  Dandan Luo; Jumin Geng; Nasi Li; Kevin A Carter; Shuai Shao; G Ekin Atilla-Gokcumen; Jonathan F Lovell
Journal:  Mol Cancer Ther       Date:  2017-07-20       Impact factor: 6.261

Review 5.  Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment.

Authors:  Yunlu Dai; Can Xu; Xiaolian Sun; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2017-05-18       Impact factor: 54.564

6.  Collagen-binding proteoglycan fibromodulin can determine stroma matrix structure and fluid balance in experimental carcinoma.

Authors:  Ake Oldberg; Sebastian Kalamajski; Alexei V Salnikov; Linda Stuhr; Matthias Mörgelin; Rolf K Reed; Nils-Erik Heldin; Kristofer Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-22       Impact factor: 11.205

Review 7.  Polysaccharide-Based Controlled Release Systems for Therapeutics Delivery and Tissue Engineering: From Bench to Bedside.

Authors:  Tianxin Miao; Junqing Wang; Yun Zeng; Gang Liu; Xiaoyuan Chen
Journal:  Adv Sci (Weinh)       Date:  2018-01-08       Impact factor: 16.806

Review 8.  Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy.

Authors:  Srinivas Ramishetti; Leaf Huang
Journal:  Ther Deliv       Date:  2012-12

9.  Pulsed focused ultrasound lowers interstitial fluid pressure and increases nanoparticle delivery and penetration in head and neck squamous cell carcinoma xenograft tumors.

Authors:  Ali Mohammadabadi; Ruby N Huynh; Aniket S Wadajkar; Rena G Lapidus; Anthony J Kim; Christopher B Raub; Victor Frenkel
Journal:  Phys Med Biol       Date:  2020-06-22       Impact factor: 3.609

Review 10.  Nanoplatforms for Targeted Stimuli-Responsive Drug Delivery: A Review of Platform Materials and Stimuli-Responsive Release and Targeting Mechanisms.

Authors:  Yuzhe Sun; Edward Davis
Journal:  Nanomaterials (Basel)       Date:  2021-03-16       Impact factor: 5.076

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.